Skip to content
HCN Grants Est. 2026
No. HT942526LCRPPCOSA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Lung Cancer Patient-Centered Outcomes and Survivorship Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated

At a glance

This program funds high-risk, high-reward research to improve lung cancer outcomes and survivorship, including quality of life, symptom management, resilience, comorbid conditions, and other patient-centered topics. Applicants must include a lung cancer patient/survivor or caregiver as an advocate on the research team, and all projects must address at least one FY26 lung cancer health outcomes and survivorship area of emphasis. U.S. Department of War organizations, foreign and domestic organizations, and for-profit or nonprofit and public or private entities may apply; the principal investigator must be an independent investigator, and awards are made to organizations, not individuals. The program expects to fund about two awards at up to $975,000 total costs each for up to 3 years, with no cost-sharing requirement. There are no stated geographic restrictions, but the program strongly emphasizes relevance to military, Veteran, and family health populations and related resources.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Researchers & Scholars
  • Biomedical & Disease Research
  • Health Care Delivery, Access & Workforce
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category. Distinctive Features: • This funding mechanism requires the research team to include an advocate who is a lung cancer patient/survivor or caregiver. • This funding mechanism allows proposed projects to include translational or clinical research, including pilot clinical trials.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide